002019.SZ
亿帆医药
SZSE · Healthcare · C 制造业 · CN
CNY 9.84
−2.86%Year over year
Reported trailing growth
- Revenue
- -1.9%
- EBITDA
- —
- EBIT
- +3.1%
- EPS
- -9.5%
- Free cash flow
- —
- Operating cash flow
- -12.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +10.2%
- EBITDA
- +29.1%
- EBIT
- +43.9%
- Net income
- +28.1%
- EPS
- +27.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026